Lisa Jones, United States says,

  • "I have been using you for over 10 years. I don't have health insurance and this is the only way I can afford my medications."
    •

    Michael Gleason, United States says,

  • "I am an American pharmacist and I buy my medications at InternationalDrugMart.com."
    •

    Donald Albright, United States says,

  • "In over two years, I have never failed to receive my medications before I ran out of my monthly supply. The online ordering is simple and fast and very much less expensive. I have saved many hundreds of dollars. Thank you."
    •

    Fredrick Hyatt, United States says,

  • "My shitzu is epileptic and without being able to order medications online from your pharmacy, I would not be able to afford to keep him. This stops his seizures and lets him be active as he should be. Thank you, Rick H."
    •

    Kimberly Arnoldt, United States says,

  • "Your prices are very reasonable at least on the meds I need. I have no insurance, so your pharmacy has been a godsend. I have recommended you to many of my uninsured friends as well."
    •

    Louis Tammaro, United States says,

  • "I ordered TOPLAP Lidocaine cream because of the great price. This cream is much more effective than the brand from my local drug store and it was much cheaper. Great customer service!"
    •
    Just look at what our Tens of Thousands of Satisfied Customers say about us
    Ask our pharmacist, if you have any questions related to your medications
    Click to know the Shipping Charges
    Get your instant Coupon now!
    Graphical representation showing How to order at International Drug MartGraphical representation showing
    How to order at International Drug Mart
    Find us on Facebook
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Novartis > February 20, 2012

      US FDA Approves Novartis' Gleevec Drug Label Change

      Novartis announces the US Food and Drug Administration (FDA) approval of the label change for its anti-cancer drug Gleevec (imatinib mesylate) to treat CD117-positive gastrointestinal stromal tumor (GIST) patients after surgery. A recent clinical study showed better results such as 54% recurrence-free survival and 55% reduced death risk in gastrointestinal cancer patients with 36 months of Gleevec treatment compared to 12 months of Gleevec treatment.

      With nearly 6000 new cases of GIST reported annually (according to Novartis), FDA’s approval of expanded use of Gleevec drug will help GIST patients to effectively manage the disease.

      Share this Article!

    Back to top^